Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cytochrome P450 polymorphisms and the response of lupus nephritis to cyclophosphamide therapy.

Clinical nephrology - 1 May 2011

Winoto J, Song H, Hines C, Nagaraja H, Rovin B H

Abstract excerpt

BACKGROUND AND AIMS: The addition of cyclophosphamide to corticosteroids significantly improves the prognosis of severe kidney involvement in systemic lupus erythematosus (SLE). However, not all patients respond to cyclophosphamide. It has been suggested that genetic variations that reduce the metabolism of cyclophosphamide reduce its effectiveness. Cyclophosphamide is metabolized and activated by the cytochrome...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Cyclophosphamide
Share to Cytochrome P-450 CYP2B6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C19

Share to Lupus Nephritis

Share to Oxidoreductases, N-Demethylating

Share to Polymorphism, Single Nucleotide

Source

Identifiers

PMID: 21543025
DOI: 10.5414/cn106886

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cytochrome P450 polymorphisms and the response of lupus nephritis to cyclophosphamide therapy.PMID 21543025Read ↗

Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.Semantic proximity Read ↗

Exploring the Correlation Between Genotypes of Drug-Metabolizing Enzymes and the Therapeutic Efficacy and Adverse Reactions of Cyclophosphamide in Childhood-Onset Lupus Nephritis: A Chinese Cohort Study.Semantic proximity Read ↗

The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation.Semantic proximity Read ↗

Genetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus.Semantic proximity Read ↗

CYP2C19 genotype does not represent a genetic predisposition in idiopathic systemic lupus erythematosus.Semantic proximity Read ↗

Genetic Polymorphisms Associated with Cyclophosphamide Outcome and Risk of Toxicity in Patients with Lupus Nephritis.Semantic proximity Read ↗

Cytochrome P450 polymorphism as a predictor of ovarian toxicity to pulse cyclophosphamide in systemic lupus erythematosus.Semantic proximity Read ↗

Epistatic interactions among CYP2C19*2, CYP3A4 and GSTP1 on the cyclophosphamide therapy in lupus nephritis patients.Semantic proximity Read ↗

Glutathione S Transferases Polymorphisms Are Independent Prognostic Factors in Lupus Nephritis Treated with Cyclophosphamide.Semantic proximity Read ↗

A pilot study of leukocyte expression patterns for drug metabolizing enzyme and transporter transcripts in autoimmune glomerulonephritis.Semantic proximity Read ↗

Pharmacogenetics and Pharmacokinetics of Immunosuppressants: Clinical Correlations and Disease Activity Control in Egyptian Female Patients with Lupus Nephritis.Semantic proximity Read ↗

Pharmacogenetics and pharmacokinetics of immunosuppressants: clinical correlations and disease activity control in Egyptian female patients with lupus nephritis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.